X4 Pharmaceuticals (XFOR) Misses Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts XFOR Hot Sheet
Join SI Premium – FREE
X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $-55.7 million.
For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tennant Co. (TNC) Tops Q3 EPS by 38c; Offer Guidance
- Palantir (PLTR) Tops Q3 EPS by 3c, Beats on Revenue; Offers FY26 Revenue Guidance
- Bioventus Inc. (BVS) Tops Q3 EPS by 1c, offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
